XBiotech Inc.

XBiotech Inc.

XBITยทNASDAQ

$2.39

-0.27%
HealthcareBiotechnology

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$72.98M
EPS-1.4900
P/E Ratio-1.61
Earnings Date05/14/2026
0.00%
Dividend Yield
3Y-
5Y-
10Y-
0.00%
Dividend Payout Ratio
3Y-
5Y-
10Y-
XBiotech Inc.

XBiotech Inc. Dividend History

XBIT ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

XBIT Dividend Payment History

XBIT ยท NASDAQ

Total Payments

1

Latest Dividend

$2.4700

Annual Amount

$2.4700

Frequency

Quarterly

DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
Jul 6, 2021
Jul 16, 2021Jul 23, 2021
$2.5000
$2.4700
Quarterly-
xbit

XBiotech Inc. Payout Ratio Analysis

XBIT ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-45.54M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.